Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06

International Journal of Radiation Oncology Biology Physics

Volumn 79, Issue 5, 2011, Pages 1323-1329

  Valicenti, Richard K ^a   Bae, Kwounghwa ^b   Michalski, Jeff ^c   Sandler, Howard ^d   Shipley, William ^e   Lin, Alex ^f   Cox, James ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biochemical failure; Dose escalation; Hormone therapy; Prostate cancer; Radiation therapy

Indexed keywords

BIOCHEMICAL FAILURE; DOSE ESCALATION; HORMONE THERAPY; PROSTATE CANCER; RADIATION THERAPY;

DISEASE CONTROL; DISEASES; ONCOLOGY; RADIATION; REGRESSION ANALYSIS;

RADIOTHERAPY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RISK FACTOR; TREATMENT DURATION; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; REGRESSION ANALYSIS;

EID: 79952663830     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.01.009     Document Type: Article

References (29)

1. Michalski J, Winter K, Perez C, et al. Toxicity following 3D radiation therapy for prostate cancer on RTOG 9406 dose level IV. Int J Radiat Oncol Biol Phys 2004;58:735-742.
2. Ryu JK, Winter K, Michalski JM, et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 94-06 level III (79.2 GY). Int J Radiat Oncol Biol Phys 2002;54:1036-1046. (Pubitemid 35292614)
3. Michalski J, Winter K, Roach M, et al. Clinical outcome of patients treated with 3D conformal radiation therapy 3D-CRT for prostate cancer on RTOG 9406. Int J Radiat Oncol Biol Phys (in press).
4. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the MDAnderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67-74. (Pubitemid 350251041)
5. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs. high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. J Am Med Assoc 2005;294:1233-1239. (Pubitemid 41352111)
6. Peeters STH, Heemsbergen WD, Koper PCM, et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch Multicenter Randomized Phase III Trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990-1996. (Pubitemid 46622106)
7. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;8:475-487. (Pubitemid 46805903)
8. Lawton CA, DeSilvio M, Roach M, et al. An update of the phase III trial comparing whole-pelvic (WP) to prostate only (PO) radiotherapy and neoadjuvant to adjuvant total androgen suppression (TAS): Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007;69:646-655. (Pubitemid 47418390)
9. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC Study): A phase III randomized trial. Lancet 2002;260:103-108. (Pubitemid 34786197)
10. Roach M, Bae K, Speight J, et al. Short term neoadjuvant androgen deprivation therapy and external beam radiotherapy for locally advanced prostate cancer. J Clin Oncol 2008;26:585-591. (Pubitemid 351264352)
11. D'Amico AV, Manola J, Loffredo M, et al. 6-Month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. J Am Med Assoc 2004;292:821-827. (Pubitemid 39079668)
12. Nakashima J, Imai Y, Tachibana M, et al. Effects of endocrine therapy on the primary lesion in patients with prostate carcinoma as evaluated by endorectal magnetic resonance imaging. Cancer 1997;80:237-241. (Pubitemid 27282317)
13. Lim JD, Hasegawa M, Sikes C, et al. Supra-additive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 1997;38:1071-1078.
14. Valicenti R, Winter K, Cox J, et al. RTOG 94-06: Is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity? Int J Radiat Oncol Biol Phys 2003;57:614-620.
15. ICRU 50 Report 50. Prescribing, recording, and reporting photon beam therapy. Bethesda, MD: International Commision on Radiation Units and Measurement; 1993.
16. Roach M 3rd, Hanks G, Thames H Jr., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-974.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy 1966;50:163-170.
19. Kim K, Tsiatis AA. Study duration for clinical trials with survival response and early stopping rule. Biometrics 1999;46:81-92.
20. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley; 1980.
21. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-1154.
22. Cox DR. Regression models and life tables. J Royal Stat Soc B 1972;34:187-229.
23. Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastasesfree survival outcomes. Int J Radiat Oncol Biol Phys 2008;71:1028-1033.
24. Laverdiere J, Gomez JL, Cusan L, et al. Beneficial effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:247-252. (Pubitemid 27138705)
25. Roach M 3rd, Lu J, Pilepich MV, et al. Predicting long-term survival, and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 2000;47:617-627. (Pubitemid 30317479)
26. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term HT after neoadjuvant HT and radiotherapy in locally advanced carcinoma of the prostate. The Radiation Therapy Oncology Group Protcol 92-02. J Clin Oncol 2003;21:3972-3978. (Pubitemid 46606211)
27. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285-1290. (Pubitemid 40470408)
28. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results fromthe Trans-Tasman Radiation Oncology Group 96.01 randomized controlled trial. Lancet Oncol 2005;6:841-850. (Pubitemid 41614795)
29. Sanguinet i G, Agostinelle S, Foppiano F, et al. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma. Br J Cancer 2002;86:1843-1847.